[go: up one dir, main page]

MA27551A1 - Composition immunogene - Google Patents

Composition immunogene

Info

Publication number
MA27551A1
MA27551A1 MA28275A MA28275A MA27551A1 MA 27551 A1 MA27551 A1 MA 27551A1 MA 28275 A MA28275 A MA 28275A MA 28275 A MA28275 A MA 28275A MA 27551 A1 MA27551 A1 MA 27551A1
Authority
MA
Morocco
Prior art keywords
ipv
formulation
immunogenic composition
antigenicity
immunogenicity
Prior art date
Application number
MA28275A
Other languages
English (en)
Inventor
Mayeresse Yves
Stephenne Jean
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32234471&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA27551(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0225532A external-priority patent/GB0225532D0/en
Priority claimed from GB0225543A external-priority patent/GB0225543D0/en
Priority claimed from GBGB0225520.6A external-priority patent/GB0225520D0/en
Priority claimed from GB0317381A external-priority patent/GB0317381D0/en
Priority claimed from GB0317371A external-priority patent/GB0317371D0/en
Priority claimed from GB0317380A external-priority patent/GB0317380D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MA27551A1 publication Critical patent/MA27551A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04—Preserving or maintaining viable microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Sampling And Sample Adjustment (AREA)

Abstract

La présente invention concerne des compositions immunogènes comprenant une formulation solide séchée ou une formulation liquide hautement visqueuse d'un poliovirus inactivé (IPV) et un agent stabilisant, l'IPV retenant son antigénicité et/ou son immunogénicité, ainsi que des procédés de fabrication de la formulation séchée d'IPV qui retient son antigenicité/immunogénicité.
MA28275A 2002-11-01 2005-05-11 Composition immunogene MA27551A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0225532A GB0225532D0 (en) 2002-11-01 2002-11-01 Drying process
GB0225543A GB0225543D0 (en) 2002-11-01 2002-11-01 Immunogenic composition
GBGB0225520.6A GB0225520D0 (en) 2002-11-01 2002-11-01 Drying process
GB0317381A GB0317381D0 (en) 2003-07-24 2003-07-24 Drying method
GB0317371A GB0317371D0 (en) 2003-07-24 2003-07-24 Immunogenic composition
GB0317380A GB0317380D0 (en) 2003-07-24 2003-07-24 Drying method

Publications (1)

Publication Number Publication Date
MA27551A1 true MA27551A1 (fr) 2005-10-03

Family

ID=32234471

Family Applications (2)

Application Number Title Priority Date Filing Date
MA28276A MA27644A1 (fr) 2002-11-01 2005-05-11 Sechage
MA28275A MA27551A1 (fr) 2002-11-01 2005-05-11 Composition immunogene

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA28276A MA27644A1 (fr) 2002-11-01 2005-05-11 Sechage

Country Status (27)

Country Link
US (3) US8409587B2 (fr)
EP (3) EP1575612B1 (fr)
JP (2) JP2006504801A (fr)
KR (2) KR101130948B1 (fr)
AR (2) AR041880A1 (fr)
AT (1) ATE352316T1 (fr)
AU (2) AU2003278166B2 (fr)
BR (1) BR0315767A (fr)
CA (2) CA2503871C (fr)
CY (2) CY1119504T1 (fr)
DE (1) DE60311526T2 (fr)
DK (2) DK2395073T3 (fr)
ES (3) ES2280809T3 (fr)
HU (1) HUE034801T2 (fr)
IL (2) IL168052A (fr)
IS (2) IS3028B (fr)
LT (2) LT2395073T (fr)
MA (2) MA27644A1 (fr)
MX (3) MXPA05004528A (fr)
MY (2) MY145693A (fr)
NO (3) NO342741B1 (fr)
NZ (2) NZ539613A (fr)
PL (2) PL213647B1 (fr)
PT (2) PT2395073T (fr)
SI (2) SI2395073T1 (fr)
TW (2) TW200501981A (fr)
WO (2) WO2004039399A1 (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003278166B2 (en) * 2002-11-01 2009-01-29 Glaxosmithkline Biologicals S.A. Immunogenic composition
CA2560513A1 (fr) * 2004-04-08 2005-12-01 Biomatrica, Inc. Integration du stockage et de la gestion d'echantillons pour les sciences de la vie
US20060099567A1 (en) * 2004-04-08 2006-05-11 Biomatrica, Inc. Integration of sample storage and sample management for life science
US20080176209A1 (en) * 2004-04-08 2008-07-24 Biomatrica, Inc. Integration of sample storage and sample management for life science
GB0409795D0 (en) * 2004-04-30 2004-06-09 Glaxosmithkline Biolog Sa Drying method
TWI398272B (zh) 2005-03-08 2013-06-11 Intervet Int Bv 化學定義的安定劑
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
UA95237C2 (uk) 2005-06-27 2011-07-25 Ґлаксосмітклайн Байолоджікалз С.А. Імуногенна композиція
US8968721B2 (en) 2005-12-28 2015-03-03 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
JP5214464B2 (ja) 2005-12-28 2013-06-19 アドバンスド バイオニュートリション コーポレーション 多糖類、糖類およびポリオール類の乾燥マトリックスを含む、ガラス形態の、プロバイオティクス細菌用送達媒体およびその製造方法
US8956625B2 (en) * 2006-09-07 2015-02-17 Glaxosmithkline Biologicals, S.A. Inactivated polio vaccines
WO2008076975A1 (fr) 2006-12-18 2008-06-26 Advanced Bionutrition Corporation Produit alimentaire sec contenant un probiotique vivant
CA2685506A1 (fr) 2007-05-02 2008-11-13 Glaxosmithkline Biologicals S.A. Vaccin
JP5307801B2 (ja) * 2007-05-18 2013-10-02 メディミューン・エルエルシー 凍結乾燥フォームによる生物活性材料の防腐
JP2010529850A (ja) * 2007-06-16 2010-09-02 エニグマ ディアグノスティックス リミテッド 組成物
GB0711683D0 (en) * 2007-06-16 2007-07-25 Enigma Diagnostics Ltd Compositions
MX2010001054A (es) 2007-07-26 2010-04-21 Sanofi Pasteur Ltd Composiciones adyuvantes antigenicas y metodos.
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
EP2410996B1 (fr) 2009-03-27 2017-08-02 Advanced Bionutrition Corp. Vaccins microparticulaires utilisables pour procéder à une vaccination et à des rappels par voie orale ou nasale chez les animaux, dont les poissons
MY157343A (en) 2009-05-26 2016-05-31 Advanced Bionutrition Corp Stable dry powder composition comprising biologically active microorganisms and/or bioactive materials and methods of making
WO2011032108A2 (fr) * 2009-09-13 2011-03-17 Vu Truong-Le Formulation pour la stabilisation à température ambiante d'un vaccin bactérien atténué vivant
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
BR112012018839B1 (pt) 2010-01-28 2020-04-14 Advanced Bionutrition Corp composição vítrea seca compreendendo um material bioativo
FR2960781B1 (fr) * 2010-06-07 2013-11-22 Sanofi Pasteur Preparation d'un vaccin oral sec stabilise, compose d'un virus vivant attenue
US9376709B2 (en) 2010-07-26 2016-06-28 Biomatrica, Inc. Compositions for stabilizing DNA and RNA in blood and other biological samples during shipping and storage at ambient temperatures
WO2012018639A2 (fr) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions de stabilisation d'adn, d'arn, de protéines salivaires et d'autres échantillons biologiques lors du transport et du stockage à températures ambiantes
PL2603100T3 (pl) 2010-08-13 2019-06-28 Advanced Bionutrition Corp. Kompozycja stabilizująca przechowywanie na sucho materiałów biologicznych
BR112013005049A2 (pt) 2010-09-02 2016-05-31 Sanofi Pasteur estabilizador para a preparação de uma composição vacina da pólio seca injetável
MX350932B (es) 2010-12-02 2017-09-26 Oncolytics Biotech Inc Formulaciones virales liquidas.
EA201390812A1 (ru) 2010-12-02 2013-11-29 Онколитикс Байотек Инк. Лиофилизированные вирусные составы
US20120222979A1 (en) 2011-03-04 2012-09-06 Elwha LLC, a limited liability company of the State of Delaware Glassy compositions
EP2694708A4 (fr) * 2011-04-07 2014-10-01 Glaxosmithkline Llc Formulations à viscosité réduite
AU2012240050B2 (en) * 2011-04-07 2016-01-21 Glaxosmithkline Llc Formulations with reduced viscosity
EP2524701A3 (fr) 2011-05-20 2012-12-19 Nitto Denko Corporation Composition pharmaceutique et son procédé de production
MX391043B (es) 2011-10-25 2025-03-21 Prothena Biosciences Ltd Formulaciones de anticuerpo y metodos.
EP2934572A4 (fr) 2012-12-20 2016-11-23 Biomatrica Inc Formulations et procédés pour stabiliser des réactifs pcr
WO2015050177A1 (fr) * 2013-10-03 2015-04-09 日東電工株式会社 Préparation de vaccin antigrippal séchée, et procédé pour produire une préparation de vaccin antigrippal séchée
WO2015091798A2 (fr) * 2013-12-19 2015-06-25 Crucell Holland B.V. Formulations améliorées pour des virosomes
WO2015123362A1 (fr) 2014-02-11 2015-08-20 Massachusetts Institute Of Technology Nouveaux anticorps anti-dengue à spectre complet
ES2786373T3 (es) 2014-06-10 2020-10-09 Biomatrica Inc Estabilización de trombocitos a temperaturas ambiente
AR101256A1 (es) * 2014-07-21 2016-12-07 Sanofi Pasteur Composición vacunal que comprende ipv y ciclodextrinas
US10711240B2 (en) 2015-06-30 2020-07-14 Societe Des Produits Neslte S.A. Composition suitable for protecting microorganisms
MY194231A (en) 2015-07-29 2022-11-23 Advanced Bionutrition Corp Stable dry probiotic compositions for special dietary uses
BR112018004400A2 (pt) 2015-09-04 2018-12-04 Inventprise Llc composições de vacina vlp estabilizadas
CN113588501B (zh) 2015-12-08 2024-12-17 生物马特里卡公司 降低红细胞沉降速率
PL3506935T3 (pl) 2016-09-02 2024-06-10 Sanofi Pasteur, Inc. Szczepionka przeciwko Neisseria meningitidis
CN112165951B (zh) * 2018-04-16 2024-12-13 默克专利股份有限公司 用于改善热稳定性的蛋白质制剂添加剂
EP3858975A1 (fr) * 2018-09-28 2021-08-04 Otsuka Pharmaceutical Factory, Inc. Solution de conservation de cellules de mammifères contenant de l'acarbose ou du stachyose
EP3897710A1 (fr) 2018-12-20 2021-10-27 Intervet International B.V. Régime de vaccination de primo-immunisation/rappel

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US509893A (en) * 1893-12-05 William griesser
DE1157734B (de) 1961-08-16 1963-11-21 Behringwerke Ag Verfahren zur Herstellung von haltbaren, oral zu verabreichenden Poliomyelitisvirus-Praeparaten
US3767790A (en) 1972-02-11 1973-10-23 Nat Patent Dev Corp Microorganisms
US3929132A (en) * 1973-04-10 1975-12-30 Alza Corp Osmotic dispenser
EP0027888B1 (fr) 1979-09-21 1986-04-16 Hitachi, Ltd. Interrupteur à semiconducteur
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
GB8323094D0 (en) 1983-08-26 1983-09-28 Franks F Preservation of cells
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
JPH0779694B2 (ja) 1985-07-09 1995-08-30 カドラント バイオリソ−シズ リミテツド 蛋白質および同類品の保護
GB8604983D0 (en) * 1986-02-28 1986-04-09 Biocompatibles Ltd Protein preservation
GB8715238D0 (en) 1987-06-29 1987-08-05 Quadrant Bioresources Ltd Food process
GB8801338D0 (en) * 1988-01-21 1988-02-17 Quadrant Bioresources Ltd Preservation of viruses
DE3819530A1 (de) * 1988-06-08 1989-12-21 Westphal Geb Jauch Christel Dr Verfahren, traeger und testsatz fuer die kultivierung und mikroskopische untersuchung von zellen
CA2005704C (fr) 1988-12-16 2003-02-11 James C. Paton Mutants de pneumolysine et vaccins antipneumococciques faits a l'aide desdits mutants
ZA907737B (en) 1989-09-29 1991-07-31 Nisshin Oil Mills Ltd Stable immunogen composition for oral administration
JPH03161441A (ja) 1989-11-20 1991-07-11 Senjiyu Seiyaku Kk メイラード反応阻害剤
EP0539492B1 (fr) 1990-07-16 2003-06-11 University Of North Carolina At Chapel Hill Proteines antigeniques a action limitee par l'incorporation de fer tirees de la bacterie n. meningitidis et associees a la famille de toxines des hemolysines
US5912336A (en) 1990-08-23 1999-06-15 University Of North Carolina At Chapel Hill Isolated nucleic acid molecules encoding transferrin binding proteins from Neisseria gonorrhoeae and Neisseria meningitidis
ES2329979T3 (es) 1990-08-23 2009-12-03 The University Of North Carolina At Chapel Hill Proteinas de union de transferencia de neisseria gonorrhoeae y neisseria meningitis. su uso como vacuna.
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
US6592876B1 (en) 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
US5476929A (en) 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
FR2682041B1 (fr) 1991-10-03 1994-01-14 Pasteur Merieux Serums Vaccins Vaccin contre les infections a neisseria meningitidis.
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
ATE245446T1 (de) 1992-02-11 2003-08-15 Jackson H M Found Military Med Dualer träger für immunogene konstrukte
WO1993018150A1 (fr) 1992-03-02 1993-09-16 Biocine S.P.A. Proteines d'helicobacter pylori utiles pour des vaccins et des diagnostics
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
RU2160120C2 (ru) 1992-05-23 2000-12-10 Смитклайн Бичам Байолоджикалс С.А. Комбинированная вакцина на основе поверхностного антигена вируса гепатита в, способ ее получения и способ предупреждения инфекции гепатита в у человека
FR2692592B1 (fr) 1992-06-19 1995-03-31 Pasteur Merieux Serums Vacc Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis et procédés les exprimant.
EP0594950B1 (fr) 1992-10-27 1999-01-27 American Cyanamid Company Vaccin pédiatrique combiné à immunogénéite augmentée de chaque constituant du vaccin
EP1300156A3 (fr) 1993-05-18 2003-05-07 The Ohio State University Research Foundation Vaccine contre l'otite moyenne
KR970704469A (ko) 1994-08-09 1997-09-06 아끼다니 죠우케이 경구용 면역원 조성물 및 그의 제조방법(Peroral Immunogen composition and Process for producing the Same)
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US6265567B1 (en) 1995-04-07 2001-07-24 University Of North Carolina At Chapel Hill Isolated FrpB nucleic acid molecule
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
ATE205724T1 (de) 1995-06-07 2001-10-15 Smithkline Beecham Biolog Vakzine mit einem polysaccharide antigen- trägerprotein konjugat und freien trägerprotein
DK0831790T3 (da) * 1995-06-07 2003-09-01 Elan Drug Delivery Ltd Fremgangsmåder til stabil inkorporering af stoffer i tørre opskummede glasmatricer og derved opnåede sammensætninger
KR19990022742A (ko) 1995-06-07 1999-03-25 샤르레 아. 테시에르 스트렙토코커스 속 유래의 hsp70 계열의 쇼크 단백질
CZ288908B6 (cs) 1995-06-23 2001-09-12 Smithkline Beecham Biologicals S. A. Kombinovaná vakcína, tato vakcína ve formě sady, způsob její výroby a její použití
DE19543770C2 (de) 1995-11-24 1998-11-05 Metallgesellschaft Ag Vorrichtung zur Messung von kondensierter Feuchtigkeit in Vorrichtungen und/oder Rohrleitungen der chemischen Technik und deren Verwendung
WO1997029773A1 (fr) * 1996-02-13 1997-08-21 The Nisshin Oil Mills, Ltd. Emulsion et poudre renfermant un vaccin et destinees a une administration orale, et procede de production associe
DE69735715T2 (de) 1996-05-01 2007-03-29 The Rockefeller University Cholin-bindendes Protein, welches als gegen Pneumokokken gerichtetes Vakzin verwendet wird
JP2000511059A (ja) * 1996-05-29 2000-08-29 ユニバーサル プリザーベーション テクノロジーズ，インコーポレイテッド ガラス化による長期貯蔵保存
US5766520A (en) * 1996-07-15 1998-06-16 Universal Preservation Technologies, Inc. Preservation by foam formation
SI9720050B (en) * 1996-07-02 2001-12-31 Connaught Lab Multivalent dtp-polio vaccines
FR2751000B1 (fr) 1996-07-12 1998-10-30 Inst Nat Sante Rech Med Adn specifiques des bacteries de l'espece neisseria meningitidis, leurs procedes d'obtention et leurs applications biologiques
DE19630390A1 (de) 1996-07-26 1998-01-29 Chiron Behring Gmbh & Co Proteine, insbesondere Membranproteine von Helicobacter pylori, ihre Herstellung und Verwendung
US5882871A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation Saliva binding protein
US5882896A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
US6420135B1 (en) 1996-10-31 2002-07-16 Human Genome Sciences, Inc. Streptococcus pneumoniae polynucleotides and sequences
US6051238A (en) * 1996-12-20 2000-04-18 Merck & Co., Inc. Stabilizers for lyophilized mumps vaccines
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
SE511963C2 (sv) 1997-04-23 1999-12-20 Ericsson Telefon Ab L M Anordning och förfarande för bestämning av linjespänning i en abonnentlinjekrets
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
EP0998557A2 (fr) 1997-07-21 2000-05-10 North American Vaccine, Inc. Compositions de pneumolysine immunogene modifiee utiles en tant que vaccins
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
BR9714980A (pt) * 1997-09-15 2001-11-06 Pasteur Merieux Msd Vacinas multivalentes
EP1032674B1 (fr) 1997-11-21 2007-01-24 Serono Genetics Institute S.A. Sequence genomique et polypeptides de (chlamydia pneumoniae), leurs fragments et leurs utilisations, en particulier pour le diagnostic, la prevention ou le traitement d'une infection
EP1032647B1 (fr) * 1997-11-26 2006-03-29 Universal Preservation Technologies, Inc. Conservation d'echantillons biologiques sensibles par vitrification
EP1032676A2 (fr) 1997-11-28 2000-09-06 Genset Sequence genomique et polypeptides de chlamydia trachomatis, leurs fragments et leurs utilisations, en particulier, pour le diagnostic, la prevention et le traitement de l'infection
GB9726398D0 (en) 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
CA2317815A1 (fr) 1998-01-14 1999-07-22 Chiron S.P.A. Antigenes du $i(neisseria meningitidis)
GB9806456D0 (en) 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
KR100794394B1 (ko) 1998-04-07 2008-01-15 메디뮨 인코포레이티드 백신용 폐렴 구균의 콜린 결합성 단백질의 유도체
GB9807721D0 (en) 1998-04-08 1998-06-10 Chiron Spa Antigen
PT1944371E (pt) 1998-05-01 2015-07-13 Novartis Ag Antigénios e composições da neisseria meningitidis
US6306345B1 (en) 1998-05-06 2001-10-23 Universal Preservation Technologies, Inc. Industrial scale barrier technology for preservation of sensitive biological materials at ambient temperatures
CA2346713A1 (fr) 1998-10-09 2000-04-20 Chiron Corporation Sequences genomiques de neisseria et procedes d'utilisation
DK1535928T3 (da) 1998-10-22 2008-10-20 Univ Montana Vaccinesammensætninger indeholdende Omp85-proteiner af Neisseria gonorrhoeae og Neisseria meningitidis
AU1722300A (en) 1998-11-12 2000-05-29 Regents Of The University Of California, The Chlamydia pneumoniae genome sequence
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
DE122009000054I1 (de) 1999-03-19 2009-12-31 Glaxosmithkline Biolog Sa Impfstoff gegen bakterielle antigene
US6245568B1 (en) 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
EP1165796A2 (fr) 1999-04-09 2002-01-02 Techlab, Inc. Support proteique recombinant de la toxine a pour vaccins conjugues polysaccharides
CA2393298C (fr) 1999-12-02 2011-02-01 Chiron Corporation Compositions et procedes de stabilisation de molecules biologiques lors dune operation de lyophilisation
JP2003520248A (ja) 2000-01-17 2003-07-02 カイロン エセ．ピー．アー． Ｎ．ｍｅｎｉｎｇｉｔｉｄｉｓ血清型ｂ外膜タンパク質を含む外膜小胞（ｏｍｖ）ワクチン
EP1790660B1 (fr) 2000-02-28 2012-06-20 Novartis Vaccines and Diagnostics S.r.l. Expression hétérologue de protéines de Neisseria
DZ3399A1 (fr) * 2000-06-29 2002-01-03 Smithkline Beecham Biolog Composition de vaccin polyvalent
WO2002002606A2 (fr) 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation contre une infection par chlamydia pneumoniae
KR100385711B1 (ko) 2000-07-05 2003-05-27 녹십자백신 주식회사 디프테리아, 파상풍 톡소이드와 백일해균 및ｂ형간염표면항원을 포함한 4가 혼합백신 및 그 제조방법
NZ594877A (en) 2000-10-27 2012-07-27 Novartis Vaccines & Diagnostic Nucleic acids and proteins from streptococcus groups A & B
WO2003009869A1 (fr) 2001-07-26 2003-02-06 Chiron Srl. Vaccins comprenant des adjuvants aluminium et histidine
CA2482448C (fr) * 2002-04-11 2014-07-08 Medimmune Vaccines, Inc. Conservation de matieres bio-actives au moyen de mousse lyophilisee
AU2003278166B2 (en) * 2002-11-01 2009-01-29 Glaxosmithkline Biologicals S.A. Immunogenic composition
GB0409795D0 (en) * 2004-04-30 2004-06-09 Glaxosmithkline Biolog Sa Drying method
US9473463B2 (en) 2014-07-29 2016-10-18 Combined Conditional Access Development & Support, LLC Control word and associated entitlement control message caching and reuse

Also Published As

Publication number Publication date
NO342741B1 (no) 2018-08-06
SI1556477T1 (sl) 2017-12-29
EP2395073A2 (fr) 2011-12-14
NO20051998L (no) 2005-06-24
IS7805A (is) 2005-04-18
US7927858B2 (en) 2011-04-19
NO20052010D0 (no) 2005-04-25
AR041880A1 (es) 2005-06-01
NO20180874A1 (no) 2005-06-24
IL168054A (en) 2011-06-30
TW200501980A (en) 2005-01-16
MX343419B (es) 2016-11-04
TW200501981A (en) 2005-01-16
EP2395073A3 (fr) 2012-01-25
PL213647B1 (pl) 2013-04-30
MY145693A (en) 2012-03-30
US20110159038A1 (en) 2011-06-30
MY132859A (en) 2007-10-31
CA2503946C (fr) 2016-08-16
EP1575612A1 (fr) 2005-09-21
AU2003278166B2 (en) 2009-01-29
PT2395073T (pt) 2017-11-24
EP2395073B1 (fr) 2017-09-06
JP2006504801A (ja) 2006-02-09
DK2395073T3 (en) 2017-10-23
EP1556477B1 (fr) 2017-08-09
ES2280809T3 (es) 2007-09-16
LT1556477T (lt) 2017-10-25
ES2649048T3 (es) 2018-01-09
NZ539706A (en) 2008-03-28
HUE034801T2 (en) 2018-02-28
IL168052A (en) 2015-03-31
JP2006512406A (ja) 2006-04-13
US8449865B2 (en) 2013-05-28
NO20052010L (no) 2005-06-24
MA27644A1 (fr) 2005-12-01
KR20050075766A (ko) 2005-07-21
LT2395073T (lt) 2017-11-10
PL215237B1 (pl) 2013-11-29
KR101130948B1 (ko) 2012-03-30
AR041881A1 (es) 2005-06-01
AU2003287980B2 (en) 2009-06-25
WO2004039417A3 (fr) 2004-12-16
US8409587B2 (en) 2013-04-02
ES2645924T3 (es) 2017-12-11
CA2503871A1 (fr) 2004-05-13
NZ539613A (en) 2008-09-26
ATE352316T1 (de) 2007-02-15
PL376950A1 (pl) 2006-01-09
MXPA05004675A (es) 2005-06-08
IS3028B (is) 2021-05-15
NO344759B1 (no) 2020-04-14
SI2395073T1 (sl) 2017-12-29
KR101058978B1 (ko) 2011-08-23
WO2004039399A1 (fr) 2004-05-13
NO20051998D0 (no) 2005-04-25
DE60311526D1 (de) 2007-03-15
CA2503946A1 (fr) 2004-05-13
MXPA05004528A (es) 2005-07-26
IS7806A (is) 2005-04-18
DE60311526T2 (de) 2007-10-31
CA2503871C (fr) 2012-12-11
AU2003278166A1 (en) 2004-05-25
US20060127415A1 (en) 2006-06-15
US20060127414A1 (en) 2006-06-15
WO2004039417A2 (fr) 2004-05-13
CY1119362T1 (el) 2018-03-07
IL168052A0 (en) 2011-08-01
JP4579156B2 (ja) 2010-11-10
HK1085380A1 (en) 2006-08-25
PT1556477T (pt) 2017-11-14
TWI332843B (en) 2010-11-11
DK1556477T3 (en) 2017-10-23
EP1556477A2 (fr) 2005-07-27
EP1575612B1 (fr) 2007-01-24
KR20050084626A (ko) 2005-08-26
BR0315767A (pt) 2005-09-06
AU2003287980A1 (en) 2004-05-25
PL377170A1 (pl) 2006-01-23
CY1119504T1 (el) 2018-03-07

Similar Documents

Publication Publication Date Title
MA27551A1 (fr) Composition immunogene
ATE290059T1 (de) Tensidzusammensetzung enthaltend geminitenside und co-amphiphile, ihre herstellung und ihre verwendung
ATE263157T1 (de) Nematizide trifluorbutene
MXPA04001224A (es) Agentes para incrementar la respuesta inmune.
WO2003000200A3 (fr) ss-2'-OU 3'-HALONUCLEOSIDES
HUP9901053A2 (hu) Fertőtlenítő készítmények és felületek fertőtlenítésére szolgáló eljárások
DE602004014167D1 (de) Pflegezusammensetzung mit aminosilicon
WO2004069152A3 (fr) ?4,5 glycuronidase et ses utilisations
ATE246202T1 (de) Gcsf konjugate
FR2821555B1 (fr) Progestatif co-micronise avec un tensioactif, composition pharmaceutique le comprenant, leurs procedes de fabrication et leurs utilisations
BR0318278A (pt) compostos de éter aminocicloexìlico e usos dos mesmo
AU6362100A (en) Derivatized polyurethane compositions and methods of making
BR0109846A (pt) Uso de uma composição que compreende um anticorpo ou um fragmento de ligação de antìgeno deste, e conjunto
BRPI0403461A (pt) composições estabilizadas contendo um agente ativo lábil ao oxigênio
GR1001067B (el) Νέες κτηνιατρικές και προστι?έμενες συν?έσεις προστασίας φυτών.
MXPA03008801A (es) Aril oxima-piperazinas utiles como antagonistas de ccr5.
PT1204659E (pt) Benzofuranos serotoninergicos
DK1546067T3 (da) Rygesammensætning
WO2002098924A3 (fr) Compositions contenant des peroxydes fluores, leurs procedes d'elaboration et leur utilisation
ATE545434T1 (de) Stabilisierte zusammensetzungen
DK1444247T3 (da) Tibolonformuleringer
BR0311974A (pt) Composições de peróxido (estabilizadas) fleumatizadas com um agente fleumatizante insaturado especìfico
FR2809960B1 (fr) Composition adjuvante de la reponse immunitaire comprenant la proteine fha ou un fragment de la proteine fha sous forme libre, et composition immunogene ou vaccinale contenant une telle composition adjuvante
BRPI0411435A (pt) método para controlar mau cheiro, e, composição desodorizante
WO2003007922A3 (fr) Formulation medicamenteuse contenant un antagoniste du ltb¿4?